<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01336049</url>
  </required_header>
  <id_info>
    <org_study_id>N+TP-AEC3</org_study_id>
    <nct_id>NCT01336049</nct_id>
  </id_info>
  <brief_title>Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer</brief_title>
  <official_title>Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nimotuzumab, as one new agent used in advanced esophageal carcinoma, has been shown to be&#xD;
      effective and safe in some studies with head-neck cancers. Advanced esophageal carcinoma have&#xD;
      poor prognosis and majority of patients resistant to chemotherapy in China. In the&#xD;
      investigators phase II clinical trial proceeded before,the combination of paclitaxel with&#xD;
      cisplatin showed good tolerance and efficacy to esophageal carcinoma. The investigators then&#xD;
      initiated a prospective phase II clinical trial with Nimotuzumabplus paclitaxel/cisplatin as&#xD;
      the 1st line treatment in advanced esophageal carcinoma to observe the efficacy and safety of&#xD;
      the combination.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>CT/MRI will be performed every 2 cycles of treatment for efficacy evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival of all participants</measure>
    <time_frame>2 years</time_frame>
    <description>OS means that from the first dose of treatment drug to death or lost, the follow-up visit will be performed every 3 months till death or lost</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>1 year</time_frame>
    <description>the follow-up visit of PFS will be performed every 2 cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 1 week</time_frame>
    <description>any adverse event will be record on CRF for safety control</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Esophageal Squamous Cell Cancer</condition>
  <arm_group>
    <arm_group_label>Nimotuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimotuzumab</intervention_name>
    <description>Nimotuzumab 200mg/week</description>
    <arm_group_label>Nimotuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Having signed informed consent&#xD;
&#xD;
          -  Age 18 to 75 years old&#xD;
&#xD;
          -  Histologically confirmed esophageal squamous carcinoma, Unresectable recurrent or&#xD;
             metastatic disease,no prior palliative chemotherapy; No prior radiotherapy except&#xD;
             radiotherapy at non-target lesion of the study more than 3 months,recurrence from last&#xD;
             adjuvant chemotherapy or adjuvant radiotherapy should be longer than 6 months; no&#xD;
             prior treatment of paclitaxel as adjuvant chemotherapy, total dose of cisplatin is&#xD;
             less than 300mg/m2 if used in adjuvant chemotherapy&#xD;
&#xD;
          -  Sex is not limited&#xD;
&#xD;
          -  Measurable disease according to the RECIST criteria(diameter of the lesion should be&#xD;
             more than 10mm by spiral CT or MRI, more than 20mm by common CT, the date of image&#xD;
             should be less than 15 days before enrollment)&#xD;
&#xD;
          -  Karnofsky performance status ≥80&#xD;
&#xD;
          -  Life expectancy of ≥ 3 month&#xD;
&#xD;
          -  WBC &gt; 4,000/mm3, absolute neutrophil count ≥2000/mm3, platelet &gt; 100,000/mm3, Hb &gt;&#xD;
             10g/dl(within 14 days before enrollment),ALT and AST &lt; 2.5 times ULN (≤5 times ULN in&#xD;
             patients with liver metastases),Bilirubin level &lt; 1.0 times ULN,Serum AKP &lt; 2.5 times&#xD;
             ULN,Serum creatinine &lt; 1.0 times ULN&#xD;
&#xD;
          -  No sever complication, such as active gastrointestinal bleeding, perforation,&#xD;
             jaundice, obstruction, non-cancerous fever &gt; 38℃；&#xD;
&#xD;
          -  Normal ECG and heart function&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Good compliance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment of palliative chemotherapy or recurrence less than 6 months from&#xD;
             time of last adjuvant chemo-/radiotherapy&#xD;
&#xD;
          -  Known hypersensitivity to Nimotuzumab,Paclitaxel,Cisplatin&#xD;
&#xD;
          -  Only with Brain or bone metastasis&#xD;
&#xD;
          -  Tumor with length ≥ 10cm, liver metastasis covers more than 50% of liver,or lung&#xD;
             metastasis covers more than 25% of lung&#xD;
&#xD;
          -  No measurable lesions, eg. pleural fluid and ascites&#xD;
&#xD;
          -  Suffer from severe heart disease or disease with other important organs&#xD;
&#xD;
          -  Chronic diarrhea or renal dysfunction&#xD;
&#xD;
          -  Pregnancy or lactation period&#xD;
&#xD;
          -  Other previous malignancy within 5 year, except non-melanoma skin cancer&#xD;
&#xD;
          -  Chronic diarrhea&#xD;
&#xD;
          -  Mentally abnormal or disable cognition,including CNS metastasis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>xiaodong zhang, MD</last_name>
    <phone>86-01-88196175</phone>
    <email>zxd0829@yahoo.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>jifang gong, MD</last_name>
    <phone>86-01-88196088</phone>
    <email>gongjifang@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xiaodong Zhang</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xiaodong zhang, MD</last_name>
      <phone>86-10-88196175</phone>
      <email>zxd0829@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>xiaodong zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>March 29, 2011</study_first_submitted>
  <study_first_submitted_qc>April 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2011</study_first_posted>
  <last_update_submitted>April 14, 2011</last_update_submitted>
  <last_update_submitted_qc>April 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>zhang xiaodong</name_title>
    <organization>Peking University, School of Oncology, Department of GI oncology</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nimotuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

